Threat Intelligence Tarot
cups · 3
Criminal (financially motivated, suspected Western)
G0085
risk 4/5
The Insider
FIN4
Pharmaceutical companiesInvestment banksHealthcare firmsSEC-regulated companies
Active since ~2013 · Insider information for securities trading, M&A intelligence, Market manipulation
The Insider does not want your credit card numbers. It wants to know if the drug trial succeeded before the press release. It targets board members, executives, and their advisors - reading emails that will move markets before markets know they should move. It trades on what it steals.
Tactics & Techniques
RCN
RDV
INI
EXC
PRS
PRV
EVA
CRD
DSC
LAT
COL
C2
EXF
IMP
T1566.002
Spearphishing Link
Initial Access
T1114.002
Remote Email Collection
Collection
T1056.001
Keylogging
Collection
T1539
Steal Web Session Cookie
Credential Access
T1213
Data from Information Repositories
Collection
T1134
Access Token Manipulation
Privilege Escalation
Notable Operations
  • 100+ pharmaceutical and healthcare company targeting for M&A intelligence
  • Targeted Board of Director and executive email accounts specifically
  • Clinical trial result data theft before public announcement
  • SEC charges against alleged operators (2015)
Defenses
  • Board and C-suite account hardening with hardware MFA
    NIST SP 800-63B
  • Email DLP monitoring for sensitive M&A and clinical data
    NIST CSF: PR.DS
  • Anomaly detection on executive email access patterns
    NIST CSF: DE.AE
  • Insider trading risk program including cyber breach monitoring
    SEC guidance
Reversed: Their Weakness
FIN4's narrow focus on insider trading intelligence made it highly identifiable - when patterns of M&A-related email compromise correlated with unusual options activity, the SEC and security researchers triangulated the connection, leading to the first major attribution of a financially-motivated cyber espionage group.

Share this adversary profile

swipe to browse

Data sourced from MITRE ATT&CK. For educational purposes.